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Background: The incorporation of genomic testing into clinical practice constitutes 
an opportunity to improve patients’ lives, as it makes possible the implementation of 
innovative, individualized clinical interventions that maximize efficacy and/or minimize the 
risk of adverse drug reactions. In order to ensure equal access to genomic testing for all 
patients, the costs associated with these tests should be reimbursed by their respective 
national healthcare systems. Given that funding for the public health sector is decreasing 
in real terms, it is of paramount importance that the emerging interventions are thoroughly 
evaluated both in terms of their clinical effectiveness and their full economic cost.
Objective: The aim of this study was to identify those genome-guided interventions that 
could be adopted and reimbursed by national healthcare systems. Further, we recorded 
the underlying factors determining the broad adoption of genome-guided interventions in 
clinical practice, in order to identify potential reimbursement criteria.
Methods: We performed a systematic review of published (PubMed-listed) scientific 
articles on the economic evaluation of those individualized clinical interventions that 
include genomic tests. Information on genomic tests reimbursed by the US Medicare 
program was also included. Subsequently, we correlated the regulatory guidance 
given for the interventions collated in our systematic review with the corresponding 
economic evaluation results and policies of the Medicare program. Regulatory guidance 
information was collected from the PharmGKB online knowledgebase and the Clinical 
Pharmacogenetics Implementation Consortium (CPIC).
Results: Most of the included studies constitute cost-utility analyses, in which the 
outcome of the interventions has been measured in quality-adjusted life years (QALYs) 
whereas an estimate of the total cost has been based upon direct medical cost data. 
Favorable economic evaluation results, as well as concrete evidence demonstrating the 
clinical utility of pre-emptive genotyping, are considered as prerequisites for the broad 
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INTRODUCTION
Genomic analysis constitutes the basic tool of personalized 
medicine, as it allows the identification of specific nucleotide 
changes in patient genomes, thereby delineating their variomes 
in relation to predisposition to genetic diseases and/or to the 
effectiveness or otherwise of specific therapeutic drugs or the 
likelihood of adverse drug reactions (Phillips et al., 2013; Lee 
et al., 2014; Phillips et al., 2016). It is thus reasonable to expect 
that the introduction of genomic testing in clinical practice will 
contribute to the rationalization of established drug-prescription 
regimens and lead to the design of new, individualized 
interventions with maximized efficacy and minimized adverse 
drug reactions (Phillips et al., 2013; Sun et al., 2013).
Health economics and economic evaluation together aim 
to allocate the limited resources available in the most effective 
ways in various healthcare systems (Williams, 1987). Faced with 
the challenge of achieving optimal benefit for patients, while 
maintaining the sustainability of national healthcare systems, 
economic evaluation analyses are deemed to be an essential part 
of the decision-making process as to whether a new intervention 
should or should not be adopted (Jonsson, 2009; McFarland, 
2014). Further, it is of great importance both in terms of patients’ 
need and equal access that these innovative interventions are 
reimbursed by national healthcare systems. To this end, there is a 
need for scientists to provide health policymakers with evidence 
of clinical validity, utility data associated with the genomic tests, 
as well as reliable evidence of economic benefit (Snyder et al., 
2014). In other words, it is essential to demonstrate i) the clinical 
utility of all pharmacogenomic biomarkers used and ii) support 
from reliable economic data demonstrating that reimbursing 
the cost of such genomic tests will not only improve patient life 
quality but also reduce the costs of the overall national healthcare 
expenditure while increasing the efficiency of the public 
healthcare sector by guiding patients to personalized treatment 
recommendations (Vozikis et al., 2016). However, the available 
clinical and financial data are still very limited, and as such, 
more reliable economic evaluation studies are urgently required 
(Snyder et al., 2014).
Most economic evaluation studies deal with cohort studies, 
be they prospective or retrospective, where a group of patients 
is monitored over time with respect to their progression in 
relation to a particular disease or after exposure to a given drug 
or risk factor (dos Santos Silva, 1999; Song and Chung, 2011). 
In economic evaluation studies, most of the prospective cohort 
studies involve hypothetical cohorts, based on hypothetical/
simulated patients. In such cases, the characteristics of 
hypothetical patients correspond to the characteristics of real 
patients taken from the literature or previous clinical trials (46)1. 
Moreover, primary data pertaining to treatment efficacy and the 
clinical progression of patients are computer-simulated. Based on 
these data, scientists can follow hypothetical cohorts of patients 
over time (77, 79).
There are four types of economic evaluation study, depending 
upon the way in which the outcome is measured and evaluated, 
namely, cost-minimization analysis (CMA), cost-effectiveness 
analysis (CEA), cost-utility analysis (CUA), and cost-benefit 
analysis (CBA) (Veenstra et al., 2000; McFarland, 2014), where 
the outcomes are measured in monetary units, number of life 
years gained (LYs), or quality-adjusted life years (QALYs), 
respectively. As a result, different utility values may be measured 
for a specific health state (Prieto and Sacristán, 2003). CUA 
studies are considered to be of the utmost importance (Veenstra 
et al., 2000), although they are subject to significant constraints. 
Common limitations include difficulties in expressing test utility 
and in interpreting test results, given the lack of actual clinical 
utility data and the heterogeneity of patients’ overall clinical 
features. As long as these limitations remain to be overcome, 
genomic tests are unlikely to be reimbursed from the public 
purse (Snyder et al., 2014). In spite of this, it is encouraging 
that the methodology of economic evaluation has improved 
considerably in recent years; at the same time, several solutions 
have been proposed in order to overcome the aforementioned 
constraints, such as conduct of sensitivity analysis and/or value 
of information analysis (Buchanan et al., 2013).
In economic evaluation analysis, cost is invariably monetized 
and is classified either as a direct or indirect medical cost, which 
is the cost associated with providing healthcare in order to deal 
with an illness or the cost related to the expenditure incurred 
by the patient and their family as a consequence of healthcare 
provision, respectively (Riewpaiboon, 2014). The cost of 
1The in-text references in italics represent the identification number of the article 
included in the systematic review literature as shown in Supplementary Table 1.
adoption and reimbursement of the costs incurred during genomic testing. Indicatively, 
pre-emptive HLA-B*5701 and TPMT testing before administration of abacavir and 
azathioprine, respectively, is reimbursed by Medicare based on both economic and 
efficacy evidence. Likewise, the medical necessary screening for MMR and BRCA1/2 
genes are reimbursed for high-risk populations.
Conclusions: Our findings further underline the need for further cost-utility analyses 
within different national healthcare systems, in order to promote the reimbursement of the 
cost of innovative genome-guided therapeutic interventions.
Keywords: economic evaluation, pricing, reimbursement, genetic and genomic tests, personalized medicine, 
quality of life, willingness-to-pay
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genomic testing falls into the category of direct medical costs 
and is therefore always taken into account by health economists 
in such economic evaluation studies. The so-called societal cost 
comprises both the direct non-medical cost and the indirect cost, 
for which there are no official records, and which may help to 
explain why societal cost is never reimbursed from public funds. 
If measurement of the total cost of an intervention is based solely 
on direct medical cost data, the analysis is from the health-payer 
perspective. By contrast, if both the direct medical cost and the 
societal cost are considered, the analysis can be said to be from a 
societal perspective (Russell et al., 1999).
In most cases, the time period of disease progression exceeds 
the period of economic evaluation; thus, there is need for 
measurement of future costs and outcomes resulting from the 
application of the new intervention, which is accomplished using 
a variety of models such as decision trees and Markov models 
for short-term and long-term analysis, relevantly (Naimark 
et al., 1997).
If an innovative intervention (in this case, genome-guided) 
outweighs the conventional intervention on the basis of 
scientific effectiveness data, the decision as whether or not to 
adopt it depends on its overall cost. If the total estimated cost 
(including the economic benefits of reducing the incidence of 
the disease) is lower than that of the conventional intervention, 
the new intervention may be described as “cost-saving” (or 
dominant) and its adoption by the national healthcare system 
is highly recommended. By contrast, the new intervention is 
said to be “dominated” by the conventional intervention as long 
as the former is more costly and less effective; in this case, the 
new intervention should be overruled or put on hold. More 
frequently, inclusion of genomic testing in clinical practice leads 
to novel interventions that exceed the cost of their predecessors 
but also prevail in terms of overall effectiveness. For this reason, 
it is important that economic evaluation analyses are performed 
in order for society to decide whether the extra cost is “worth” 
paying (in order to reap the societal benefits of genomic testing). 
The decision to adopt a new intervention depends on the amount 
of money that society is willing to spend on each QALY gained 
(willingness-to-pay threshold). Whether the incremental cost-
utility ratio (ICUR) of an intervention lies below or above this 
threshold determines the likelihood (or not) of being adopted by 
the national healthcare system (Bertram et al., 2016).
The willingness-to-pay threshold varies with respect to 
the country (e.g., $50,000–$100,000/QALY in the United 
States, £20,000–£30,000/QALY in the UK, etc.). (Stolk et al., 
2004; Mccabe et al., 2008). In the absence of officially declared 
thresholds, health economists suggest a range of thresholds 
based on the medical literature and other official data, such as 
the per capita gross domestic product as suggested by the WHO 
(Marseille et al., 2014).
The Medicare program is the largest third-party payer that 
provides reimbursement for medical services on behalf of US 
citizens (De Lew, 2000). Eligible for Medicare coverage are 
US citizens aged 65 or older who have worked in the US and 
have paid payroll taxes, employees in government agencies, 
as well as people under the age of 65 with certified disability. 
Insurance coverage can also be provided through the spouse’s 
work. The federal agency responsible for managing the 
Medicare program is the Centers for Medicare and Medicaid 
Services (CMS) and is responsible for concluding contracts 
with private insurance companies to serve as fiscal agents 
between healthcare service providers and the US government 
(De Lew, 2000).
Although genomic tests constitute a useful tool for the 
diagnosis and personalized treatment of genetic diseases, 
concerns about their validity and cost hinder their extensive use 
in clinical practice and, subsequently, reimbursement. Here, we 
have conducted a systematic review of scientific articles describing 
the economic evaluation of individualized interventions, with 
the aim of recording the important characteristics of economic 
evaluation analysis, as well as evaluating the different genomic 
tests in terms of both their cost and effectiveness. The main 
objective of this approach is to identify those interventions that 
are more likely to be reimbursed by national healthcare systems. 
Furthermore, we triangulated the regulatory guidance of the 
genome-guided interventions recorded in our study with the 
corresponding economic evaluation results and reimbursement 
policies of major programs, such as Medicare. Such a correlation 
should reveal the criteria that need to be met in order for a new 
therapeutic intervention to be broadly implemented in the clinic 
and then reimbursed.
METHODS
A systematic literature search was conducted using the PubMed 
database using the following search terms: “pricing and genomics,” 
“pricing and personalized medicine,” and “reimbursement and 
genomic tests.” Using the aforementioned terms, a total of 2,843 
publications were collected, from which 2,686 publications were 
not processed further, based on their title and/or their abstract. 
From the remaining 157 publications, the full text was obtained 
in order to assess their suitability in accordance with the main 
purpose of this review, based on the following criteria. Firstly, 
only publications that were published since 2006 were included. 
Secondly, every enquiry had to be an economic evaluation of a 
therapeutic strategy involving one or more genomic tests assessed 
in comparison to another more or less applied therapeutic 
strategy not involving genomic tests. Another essential inclusion 
criterion was the nature of the economic evaluation study, which 
had to have been appropriately conducted. Moreover, clear 
reference must have been made either to the trade name of the 
test or the gene(s) examined, as well as to the disease(s) for 
which the therapeutic recommendations were designed. Based 
on the above criteria, 64 publications were rejected, leaving 96 
publications to be further evaluated in this systematic review 
(Supplementary Table 1). The overall search methodology is 
depicted in Figure 1.
The 96 scientific articles were examined in detail in order 
to gather all the available information relevant to the scope of 
the present study. More specifically, we collected information 
pertaining to the nature of the economic evaluation studies 
(Supplementary Table 2) and the corresponding individualized 
interventions (Supplementary Table 3), while collating 
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quantitative data, such as the cost of the genomic tests, the 
overall cost of the new interventions and their corresponding 
cost-utility, and/or cost-effectiveness ratios (Supplementary 
Table 4). Our literature mining effort was enriched with further 
data on those genomic tests that are reimbursed by the Medicare 
program. Emphasis was placed on the Medicare program, as 
its reimbursement policies constitute basic principles for many 
private insurance payers (Ball, 1995).
We subsequently cross-correlated the genome-guided 
therapeutic interventions reported in our literature review with 
the corresponding guidance from the American regulatory body, 
the Food and Drug Administration (FDA), as well as the online 
Clinical Pharmacogenetics Implementation Consortium (CPIC, 
2019) resource (https://cpicpgx.org). Of note, we collected the 
FDA-approved drug labels via the PharmGKB knowledgebase 
(PharmGKB, 2019). “PharmGKB” is an online knowledge 
FIGURE 1 | Overview of the article querying methodology in the PubMed literature database.
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resource that integrates the pharmacogenomic information 
which is documented in the drug labels of major regulatory 
bodies, such as the FDA. In terms of the requirement to conduct 
a pharmacogenomic test before the administration of a given 
drug, pharmacogenomic testing may be classified as “required,” 
“recommended,” “actionable PGx,” or “informative PGx” in 
order of decreasing necessity (https://www.pharmgkb.org/). As 
far as the CPIC® is concerned, it is an international consortium 
that provides freely available, evidence-based, and detailed 
gene/drug clinical practice guidelines in an effort to overcome 
the barrier of the implementation of pharmacogenomic testing 
in the routine clinical setting. CPIC has already published 
21 guidelines covering 44 gene-drug pairs that have been 
meticulously curated and systematically updated. For each gene-
drug pair, CPIC assigns a corresponding level ranging from 
A–D (in order of decreasing necessity). As far as the gene-drug 
correlations classified as CPIC level A are concerned, it is highly 
recommended that prescription of the affected drug should 
be changed with regard to the available genetic information, 
given that the strength of such a recommendation is of high or 
moderate importance. CPIC level B supports similar action in 
terms of clinical context while bearing in mind that alternative 
therapies/dosing are likely to be as effective and as safe as non-
genetically based dosing (https://cpicpgx.org/).
RESULTS
In the present systematic review, we examined only economic 
evaluation studies published since 2006, the majority of 
which were published after 2010. More specifically, only 23 
publications  were published between 2006 and 2010, while 73 
publications were published between 2010 and the present. The 
number of studies published per year is presented in Figure 2A. 
Moreover, the majority of the studies were performed either in 
a European country (34 studies) or in the USA (41 studies). The 
majority of the economic evaluation studies were conducted 
in two countries, namely, the USA (39 studies) and the United 
Kingdom (10 studies). The number of publications per country is 
presented in Figure 2B.
Qualitative Characteristics of Economic 
Evaluation Studies
Cohort Study and Economic Evaluation Model
In this systematic review, 83 prospective cohort studies and 13 
retrospective cohort studies were identified. It should be noted 
that 80 of the 83 prospective studies were based on hypothetical 
cohorts of patients, while only three were based on real patients. 
The models used with regard to the measurement of future costs 
and outcomes are presented in Figure 2C.
Measurement of Outcome and Cost
In our systematic review, 27 studies employed CUA, 17 CEA, 
while only two adopted CMA. 40 publications employed a 
combination of CEA and CUA, whereas one was a combination 
of CEA and CMA. The remaining nine publications were simple 
economic analyses, as the interventions were evaluated taking 
into consideration only the total cost of each intervention.
Further, regarding the measurement of the outcome, in 44 
publications, the outcome was measured in QALYs and in 12 
publications in LYs, whereas in 23 publications, a combination 
of QALYs and LYs was preferred. In the vast majority of the 
publications included in this study (76 out of 96 studies), the 
researchers took into consideration only the direct medical cost 
when determining the total cost of individualized interventions. 
The applied methods of measuring the outcome and cost in all 
studies are presented in Figure 3.
Estimation of Cost-Effectiveness and 
Cost-Utility of Individualized Interventions
In our systematic review, we attempted to establish which 
interventions were likely to be adopted by each national 
healthcare system in their corresponding countries, based on 
the available willingness to pay threshold. The “cost-saving” 
interventions suggested to be adopted and reimbursed are 
shown in Table 1. Moreover, the interventions that were found 
to be either cost-effective or not, according to ICUR data, and 
the willingness to pay thresholds (suggested by authors) are 
presented in Supplementary Tables 5A and Supplementary 5B, 
respectively.
Regulatory Instructions and Economic 
Evaluation in Reimbursement Decisions
Subsequently, we aimed to cluster the pharmacogenomic 
correlations for which we have collected evidence from the 
Medicare program regarding the corresponding guidance and 
economic studies conducted (Tables 2 and 3). As may be readily 
assumed, those gene-drug correlations that have the strongest 
evidence to support the necessity of genetic testing, and that 
are accompanied by reliable cost-utility studies which prove the 
cost-effectiveness of pre-emptive genotyping, are those that are 
reimbursed. Abacavir-HLA-B*5701 probably constitutes the best 
example of the concordance between scientific and economic data. 
Indeed, both the FDA and CPIC highlight the contraindication of 
this medication to carriers of the HLA-B*5701 allele due to the high 
risk of hypersensitivity reactions (HSR) (Centers for Medicare & 
Medicaid Services, 2018; BlueCross Blueshield of Western New 
York, 2018; Quest Diagnostics, 2015; PGX Tests Determined to 
be Medicially Necessary for Medicare Coverage.; Local Coverage 
Determination (LCD)), while economic evaluation results with an 
ICUR of $36,700/QALY (lower than the $50,000/QALY threshold) 
justify its cost-effectiveness (60). Another noteworthy gene-drug 
correlation is the TPMT-azathioprine; pre-emptive genotyping 
(for the administration of this drug) is classified as level A by 
CPIC and “recommended” by the FDA, indicating that changes 
in dosing should be done with regard to the pharmacogenomic 
results. Apart from the aforementioned strong clinical evidence, 
adoption and reimbursement of TPMT testing (Local Coverage 
Determination (LCD); Blue Regence, 2019) are also supported 
by the results of economic evaluation, given that TPMT testing 
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FIGURE 2 | (A) Number of publications per year, (B): number of publications per continent/country: Europe (others): Austria (n = 1), France (n = 2), Germany 
(n = 2), Denmark (n = 1), Switzerland (n = 3), Sweden (n = 1), Spain (n = 5), Italy (n = 1), Croatia (n = 1), Serbia (n = 1), Asia: China (n = 5), Japan (n = 3), 
South Korea (n = 1), Singapore (n = 4), Thailand (n = 3), Oceania: Australia (n = 3), New Zealand (n = 2), (C): models used for measurement of future costs 
and outcomes.
Reimbursement of Personalized Medicine InterventionsSimeonidis et al.
7 August 2019 | Volume 10 | Article 830Frontiers in Pharmacology | www.frontiersin.org
in idiopathic pulmonary fibrosis prior to azathioprine treatment 
has an ICUR of $49,156/QALY, below the US $50,000/QALY 
threshold (27).
In our literature mining effort, we also identified 
pharmacogenomic correlations with variable economic results. 
Regarding the cost-effectiveness of HLA-B*1502 genotyping in 
relation to carbamazepine or phenytoin treatment, the results 
differ; some of them demonstrate that pharmacogenomic 
testing is cost-effective, whereas others do not. However, it is 
noteworthy that carbamazepine has a boxed warning on its 
FDA drug label stating that screening for HLA-B*1502 allele 
is required to be carried out prior to treatment in patients 
FIGURE 3 | Measurement of cost (A) and outcome (B) in the articles analyzed within this study.
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that are genetically at-risk due to the high risk of serious and 
sometimes fatal dermatological reactions. CPIC guidance concurs 
with that of the FDA, strongly recommending the use of an 
alternative drug in case patients are HLA-B*1502 carriers and 
carbamazepine-naïve. Similarly, both on the FDA phenytoin 
label and in the corresponding CPIC guideline, it is documented 
that consideration should be given to avoiding phenytoin 
as an alternative for carbamazepine in patients positive for 
TABLE 1 | Cost and number of quality-adjusted life years (QALYs) of “dominant” individualized interventions.
Disease Gene Cost of intervention Number of QALYS Reference++
W/o PGx test/test 1 With PGx test/test 2 W/o PGx test/
test 1
With PGx 
test/test 2
Advanced 
adenocarcinoma
of the lung
EGFR SG$47,100 SG$44,700 0.87 0.91 (Lee et al., 2014)
Colorectal cancer KRAS ¥3,160,000($35,000) ¥2,600,000 ($29,000) 0.48 0.49 (Sun et al., 2013)
UGT1A1 $13,058 $12,786 1.6347 1.6349 (54)
Acute coronary 
syndrome
CYP2C19 $15,800 $14,900 0.966 0.9665 (Jonsson, 2009)
NZ$85,342 NZ$84,646 8.544 8.650 (Hess et al., 2015)
$76,906* (CLO) $76,450 7.4381 7.5301 (47)
$78,296 (P2Y12)
Neonatal diabetes KCNJ11, ABCC8 $71,784 $59,256 16.29 16.99 (Song and Chung, 
2011)
Atrial fibrillation 4q25 Cost saving of $250,689 Net gain of 8.8 (Riewpaiboon, 2014)
Familial adenomatous 
polyposis
APC €13,928.82 (Spain) €8,038.93 19.92 19.93 (65)
Neovascular macular 
degeneration
CFH, ARMS2/
HTRA1, C3, C2, 
CFB
Cost saving of $493 Gain of 0.0392 (78)
Venous 
thromboembolism
Thrombo inCode® €1,366.30–€2,795.61 
(Spain)
€832.58–€848.38 8.2586–8.4784 8.5871–8.5874 (61)
Breast cancer MammaPrint® €17,869+ (Spain) €16,989 18.131 18.357 (Snyder et al., 2014)
$27,882+ $21,598 7.364 7.461 (53)
*Currency used is different from the currency of the country in which the corresponding economic evaluation study was carried out. Researchers chose to express costs in US $ ($). +Cost 
of individualized intervention including Oncotype DX®. PRA, prasugrel; CLO, clopidogrel; P2Y12, other P2Y12 inhibitor (individualized interventions including prasugrel, clopidogrel 
and other P2Y12 inhibitors, respectively). ++Identification number of the article (Supplementary Table 1).
TABLE 2 | Pharmacogenomic tests covered by Medicare.
Drug Allele FDA CPIC ICUR Willingness-to-
pay threshold
Type Reference++
Abacavir HLA-B*5701 Required A $36,700/QALY $50,000–
$100,000/
QALY
CE (60)
– – DT (64)
Azathioprine TPMT Recommended A $49,156/QALY $50,000/QALY CE (BlueCross Blueshield of 
Western New York, 2018)
Carbamazepine HLA-B*15021 Required A $85,697/QALY $50,000/QALY Not CE (Stolk et al., 2004)
$29,750/QALY $50,000/QALY CE (De Lew, 2000)
Cetuximab KRAS Required – – – Cost saving, same 
effectiveness
(44)
Clopidogrel CYP2C192 Actionable A – – Dominant (Jonsson, 2009, 47)
$4,200/QALY $100,000/QALY CE (Meckley and Neumann, 2010)
Crizotinib ALK Required – $136,000/QALY $200,000/QALY CE (Blue Regence, 2019)
Erlotinib EGFR Required –
Erlotinib EGFR Required – $110,658/QALY $100,000/QALY Not CE (86)
$162,018/QALY $150,000/QALY Not CE (63)
Panitumumab KRAS Required – – – Cost saving, same 
effectiveness
(44)
Phenytoin HLA-B*15021 Actionable A $85,697/QALY $50,000/QALY Not CE (Stolk et al., 2004)
$29,750/QALY $50,000/QALY CE (De Lew, 2000)
Trastuzumab ERBB2 (HER-2) Required – – –
Vemurafenib BRAF Required – – –
1HLA-B*1502 is regarded medically necessary and thus reimbursed only for patients of Asian ancestry. 2CYP2C19 testing is regarded as medically necessary only for patients with 
ACS undergoing PCI who are initiating or reinitiating Clopidogrel therapy. CE, Cost-effective; DT, Dominant. ++Identification number of the article (Supplementary Table 1).
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HLA-B*1502. Therefore, even though the economic results cannot 
lead to a definite conclusion as far as the reimbursement policy 
that should be applied, the clinical evidence that lies behind 
these pharmacogenomic correlations supports the broad clinical 
adoption of pre-emptive testing in patients of Asian ancestry 
(BlueCross Blueshield of Western New York, 2018; IGNITE 
Implementing GeNomics In practice, 2018; Local Coverage 
Determination (LCD)).
With the exception of those gene-drug correlations whose 
economic data are inconclusive, there are also pharmacogenomic 
biomarkers whose economic benefits remain to be assessed or 
whose economic results clearly discourage reimbursement. 
According to the FDA drug label, erlotinib is a tyrosine kinase 
inhibitor indicated for first-line treatment of patients with 
metastatic non-small cell lung cancer (NSCLC), whose tumors 
are characterized by epidermal growth factor receptor (EGFR) 
exon 19 deletions or exon 21 (p.L858R) missense mutations. 
The FDA indicates that patients being considered for erlotinib 
treatment should first be tested for the aforementioned mutations 
by means of an FDA-approved test as neither the safety nor the 
efficacy of erlotinib have been established in NSCLC patients 
whose tumors have other EGFR mutations. EGFR testing is 
part of the Medicare reimbursement fee schedule (Centers for 
Medicare & Medicaid Services, 2018; PGX Tests Determined 
to be Medically Necessary for Medicare Coverage; Local 
Coverage Determination (LCD); Hess et al., 2015), despite the 
fact that no economic evaluation analysis has been performed 
which shows that testing for over-expression of EGFR prior to 
erlotinib treatment can be cost-effective; in all analyses, the new 
interventions exceed the $100,000/QALY threshold (63, 86). 
However, the decision to allow reimbursement appears to have 
been influenced by strong clinical evidence documented on the 
FDA drug label, suggesting that testing for overexpression of 
EGFR contributes to achieving an optimal therapeutic effect 
in both lung and colon cancers. The example of vemurafenib-
BRAF should also be mentioned, as this pharmacogenomic 
test is also reimbursed by Medicare (Centers for Medicare & 
Medicaid Services, 2018; IGNITE Implementing GeNomics In 
practice, 2018; Local Coverage Determination (LCD); Hess et 
al., 2015) even in the absence of economic evaluation studies. 
Based on the mechanism of action of this tyrosine kinase 
inhibitor, the FDA drug label states that vemurafenib is only 
indicated for the treatment of patients with unresectable or 
metastatic melanoma with BRAF p.V600E mutation as detected 
by an FDA-approved test.
As far as genomic tests are concerned, we aimed to cross-
correlate the Medicare reimbursement policies with results from 
cost-utility analyses from our systematic review. In general, 
Medicare covers genomic tests that are regarded as medically 
necessary by the Centers of Medicare & Medicaid Services. 
More specifically, screening for MMR variants in colorectal 
tumors is regarded as medically necessary only for colorectal 
cancer patients (and then only for whose family members 
meet specific criteria/the revised Bethesda guidelines) (Local 
Coverage Determination (LCD)). Precautionary MMR testing 
in individuals who are at-risk of developing colorectal cancer 
and/or Lynch syndrome is considered experimental and hence 
not medically necessary. It is encouraging though that there are 
economic evaluation results which suggest that precautionary 
testing for MMR mutations in unaffected individuals with a 
family history of colorectal cancer is cost-effective, with an ICUR 
of $26,000/QALY (91). Another example is testing for BRCA1/2 
genes, which constitute well-established pharmacogenomic 
biomarkers for breast cancer, as specific mutations in these 
genes have been associated with a greatly increased risk of 
developing breast cancer. BRCA1/2 testing is covered mostly 
for affected individuals with a family history of breast cancer 
and occasionally for healthy individuals with suspected breast 
cancer and/or breast cancer history (Centers for Medicare & 
Medicaid Services, 2018; Local Coverage Determination (LCD); 
Beattie et al., 2012; Meckley and Neumann, 2010). However, 
economic evaluation results indicate that precautionary testing 
for BRCA1/2 is cost-effective with an ICUR of $9,000/QALY) 
even in healthy/unaffected women with a family risk of breast 
cancer (36).
DISCUSSION
Personalized medicine targets health care interventions to 
subgroups of patients, who share specific biological and genetic 
characteristics. The most commonly used applications are genomic 
tests, which dominate the era of personalized medicine and, thus, 
constitute the main focus of this study, as far as their pricing and 
reimbursement are concerned. Pre-emptive genotyping leads 
to new individualized drug treatment interventions, where the 
appropriate drug is administered to each patient in an effort 
to minimize the incidence of drug toxicity or lack of efficacy. 
Hence, diseases are treated more effectively, while the quality of 
the patient’s life improves. At the same time, national healthcare 
systems benefit from the expected reduction in expenditure on 
unnecessary medical procedures and/or the hospitalization 
of patients suffering from adverse drug reactions resulting 
from inadequate therapies. However, it should be noted that 
TABLE 3 | Genomic tests covered by Medicare.
Allele FDA CPIC ICUR Willingness-to-pay 
threshold
Type Reference++
MMRgenes – – $26,000/QALY $50,000/QALY CE (91)
BRCA1/23 – – $9,000/QALY $50,000/QALY CE (Gavan et al., 2018)
3BRCA1/2 testing is regarded as medically necessary only for patients with breast cancer and healthy individuals with a family history of breast cancer. ++Identification number of the 
article (Supplementary Table 1).
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personalized medicine also includes other forms of applications, 
such as algorithm-based prescribing, population-based screening 
programs etc., which were not taken into consideration in the 
present study (Gavan et al., 2018; Vizirianakis et al., 2019).
The heterogeneity of patients’ specific characteristics (phenotype) 
due to genome-variants leads to the heterogeneity in patients’ drug 
treatment response and/or development of adverse drug reactions. 
Researchers consider this patient-level heterogeneity, while 
conducting economic evaluation analysis, as it affects both total 
treatment costs and outcomes (Gavan et al., 2018). This is why many 
national health care agencies, for instance the National Institute 
for Health and Care Excellence (NICE) for England and Wales, 
suggest that sub-group analyses should be conducted in order to 
make decisions about implementation of new health technologies 
(including genomic tests) in clinical practice (Espinoza et al., 2014).
Genomic tests are also directed to particular populations, for 
example, patients suffering from rare diseases that cannot be 
easily treated with conventional interventions. Indicatively, in 
our systematic analysis, there were studies, in which pre-emptive 
genotyping for the diagnosis of rare diseases (hypertrophic 
cardiomyopathy, Cowden syndrome, neovascular macular 
degeneration, neurofibromatosis etc.) was evaluated. Moreover, 
there are applications of genomic tests even in unborn children. 
In our systematic review, we identified studies evaluating 
prenatal screening for spinal muscular atrophy, cystic fibrosis, 
and X-linked hemophilia.
Two essential parameters emerge as fundamental preconditions 
for a pharmacogenomic test to be broadly adopted in the clinic 
and for it to be reimbursed: concrete evidence of the relevant gene-
drug correlation, as well as favorable economic evaluation results. 
As implied by our literature review, the strong classification of the 
pharmacogenomic information by the CPIC and/or FDA guidance 
constitutes a key factor in reimbursement decision making, 
even in the absence of favorable economic results as illustrated 
by the pharmacogenomic correlations of vemurafenib-BRAF 
and erlotinib-EGFR. Pre-emptive genotyping is often deemed 
crucial for a specific population, the so-called high-risk groups. 
In particular, treatment with carbamazepine is strongly associated 
with a high risk of developing Stevens-Johnson syndrome and toxic 
epidermal necrolysis (SJS/TEN) in carriers of the HLA-B*1502 
allele. Given that this inherited allelic variant is mainly observed in 
patients of Asian ancestry, the corresponding pharmacogenomic 
test is only reimbursed for patients with Asian ancestry (Centers 
for Medicare & Medicaid Services, 2018; Local Coverage 
Determination (LCD)). Ιn parallel, although BRCA1/2 constitutes 
a well-established genomic biomarker for the development of 
breast cancer, BRCA1/2 genetic testing is considered medically 
necessary and, thus, uniquely covered for individuals with a family 
history of such a disease (Beattie et al., 2012).
As far as the economic evaluation results are concerned, it 
is of paramount importance that the pharmacogenomic tests 
are proven to be either “cost-saving” or at least cost-effective in 
economic terms, in other words, that the proposed therapeutic 
intervention is also cost-saving, apart from being more effective, 
than the already established one. Given that the inclusion of pre-
emptive genotyping often increases the cost of the therapeutic 
recommendation, the eventual decision depends upon the 
willingness-to-pay thresholds, which serve to ensure the 
affordability of the new interventions. An indicative example of 
just such a cost-effective pharmacogenomic test which meets the 
aforementioned criteria is HLA-B*5701 genotyping prior to the 
initiation of abacavir treatment in HIV patients. More specifically, 
the agreement of both FDA and CPIC about the necessity of 
pre-emptive HLA-B*5701 genotyping, as well as the favorable 
economic evaluation results ($36,700/QALY at a willingness-to-
pay threshold of $50,000/QALY), justifies the reimbursement of 
this pharmacogenomic test by Medicare (60).
In our study, we focused on the US Medicare program, as there 
are limited data regarding reimbursement of genomic testing in 
countries of the European or Asian region. More specifically, 
as far as the European Union is concerned, each member state 
has a different reimbursement policy, as each country spends 
a different amount of budget on the health sector. In addition, 
there is a different percentage of private and public insurance 
contribution in reimbursement of healthcare services. Some 
countries have approved reimbursement exclusively from public 
or private insurance funds, while others from a combination 
of them. As a result, there is no uniform regulatory framework 
providing precise instructions and provisions on the conditions 
and the exact procedure for reimbursement of genomic tests 
from the public funds (Vozikis et al., 2016).
Most economic evaluation studies in our systematic review 
were cost-utility analyses. However, the credibility of economic 
evaluation analysis is negatively affected by the lack of actual 
clinical utility data from genomic testing in real patients (Snyder 
et al., 2014). Indeed, 80 out of 96 studies in our systematic 
review were based on hypothetical cohorts, where hypothetical 
patients and simulated clinical data from older clinical trials were 
used. Furthermore, the use of retrospective cohorts also raises 
concerns about the quality of the results produced. There were 
13 retrospective studies in our systematic review, which accounts 
for a significant proportion of the total number of publications. 
More specifically, a retrospective study design may be associated 
with poorer data quality, as it is based on data from healthcare 
databases that have already been collected. This increases the risk 
of selection bias, which refers to the selection of inappropriate 
individuals that are unrepresentative of the population that 
researchers wish to study. Moreover, inaccurate or incomplete 
recollections from the past of the cohort’s individuals (recall bias) 
may also lead to questionable economic evaluation results.
Elaborating more on the economic evaluation method, economic 
evaluation from a societal perspective is considered more complete 
and more reliable, in comparison to the corresponding analysis from 
the health-payer perspective (Jonsson, 2009). It is well known that 
due to the lack of official societal cost recordings and the general 
targeting of reimbursement programs in the so-called direct medical 
cost, most studies are orientated from the health-payer perspective. 
This tendency, which is also confirmed by our systematic review 
results, indicates the need for more cost-utility analyses from the 
societal perspective, in order to allow optimal (societal) decisions 
to be made. It is encouraging that the methodology of economic 
evaluation has improved significantly with the development of 
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statistical models that enable forecast of the interventions’ overall 
cost and clinical effectiveness over time, providing even life-time 
analysis (Naimark et al., 1997; Payne et al., 2018). More specifically, 
in 31 studies covered in our systematic review, both short-term and 
long-term analyses were achieved using a combination of decision 
trees and Markov models. Taking into account 11 additional studies 
in which only Markov models were used, long-term analysis was 
achieved in almost half of the studies under this systematic review.
In model-based economic evaluation analyses, uncertainty 
may also arise because of difficulties in estimating the true 
value of varying parameters (variables), which are used in 
the aforementioned models. Such variables usually constitute 
the cost of health care interventions or the age of patients. The 
models used in economic evaluation offer the opportunity to 
estimate the impact of parameter uncertainty using probabilistic 
sensitivity analysis. Taking into consideration the potentiality 
of long-term analysis of incremental costs and outcomes, it is 
of no doubt that model-based economic evaluation constitutes 
the preferred approach in decision making (Payne et al., 2018).
Conclusions and Future Perspectives
National healthcare systems are often unable to cope with the 
ever-increasing social needs for high-quality healthcare service 
provision. Over the decades, the rapid growth of the population, 
the increasing economic resources of national economies, and the 
increasing cost of healthcare provision have led to a marked increase 
in the annual health expenditure in Western countries (McFarland, 
2014). However, funding for the public health sector has decreased 
since the 2008 financial crisis, and as a result, qualitative selection 
among different medical interventions has to be made.
In relation to the role of economic evaluation in public health 
policy-making, there is an urgent need for the establishment of 
national policies that favor the conduct of economic evaluation in 
state-owned research institutes and universities, as well as in the 
private sector. It is encouraging that in recent years, the number of 
published economic evaluation analyses in the field of genomic and 
personalized medicine has continued to increase. This tendency 
accords with our systematic review results, which highlight the 
increasing number of publications since 2011. However, and in 
accordance with our findings from this study, more cost-utility 
analyses should be conducted in various countries in order to cover 
as many populations and ethnic groups as possible. By contrast, only 
a few relevant analyses have been conducted in Asian and African 
countries. Given the high frequency of high-risk and actionable 
alleles in Asian and African populations, it might reasonably be 
expected that researchers would be especially interested in economic 
evaluation of genomic testing in these countries. Taking into 
consideration the recorded mortality rates in low income Asian and 
African countries, pharmacogenomic research would contribute to 
the mitigation/prevention of global health inequalities.
Another crucial issue to be investigated is the economic 
thresholds. Based on our findings, there are no strictly defined 
willingness-to-pay thresholds even for a specific country’s national 
health system. Given existing social inequalities, health economists 
suggest that the commonly used thresholds should be expanded. 
The lack of concordance between the budgetary capability of the 
national health systems and the needs of local societies have led 
to the use of expanded willingness-to-pay thresholds suggested 
by health economists (Eichler et al., 2004; Neumann et al., 2014). 
In other words, it is likely that the persistence in strictly defined 
economic thresholds could lead to a fruitless controversy between 
public health providers and specific social groups or patients, 
while underestimating the scientifically proven clinical utility of 
genomic testing. Moreover, the interventions under evaluation 
are developed against diseases, which differ in terms of their 
severity, their pathophysiological mechanisms, and, consequently, 
their treatment regimens and cost. As a result, apart from social 
inequalities and other socio-economic factors, it would be 
scientifically inappropriate to use a strictly defined threshold for 
universal assessment of dissimilar interventions.
Many studies considered in this systematic review 
concluded that genomic-guided treatment may represent 
a cost-saving or cost-effective strategy against various 
diseases, including different types of cancer. Many of these 
strategies include genomic tests that are reimbursed by the US 
Medicare program, which is indicative of the leading role of 
economic evaluation results in determining reimbursement 
policymaking. Unsurprisingly, most of the non-cost-effective 
interventions are not covered by Medicare. Apart from the 
unfavorable economic evaluation results, which clearly do not 
provide a cogent argument for reimbursement, the decision 
not to cover the cost of the relevant genomic tests is mainly 
attributed to insufficient evidence supporting their clinical 
utility (Hess et al., 2015; Local Coverage Article: MolDX). It 
should be mentioned that this claim is more aligned with FDA 
regulations than with CPIC guidance.
Furthermore, our systematic review results emphasize the 
wide range of potential genomic testing applications, including 
interventions against colorectal and breast cancer, as well as acute 
coronary syndrome, cardiovascular disease, neonatal diabetes, 
and macular degeneration (Table 1, Supplementary Table 5A). 
Additional analyses could usefully be performed in order to 
enrich the already favorable economic evaluation data, in an 
effort to ensure positive reimbursement decisions by the national 
healthcare systems.
Last, but not least, the adoption of an appropriate universal 
legal framework is deemed necessary in order to determine the 
appropriate conditions for reimbursement of clinically valid 
tests. It should be noted that a basic precondition for achieving 
this goal is the foundation of a stable, effective, and transparent 
pricing system to avoid overpricing.
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